COMAP: Controling Mean Arterial Pressure Using a Closed-Loop System for Vasopressor Titration

Sponsor
Clinique de la Sauvegarde (Other)
Overall Status
Completed
CT.gov ID
NCT04586218
Collaborator
Bicetre Hospital (Other), Erasme University Hospital (Other)
40
1
2
21
58

Study Details

Study Description

Brief Summary

The investigators have developed an automated vasopressor controller to improve the titration of vasopressor in order to maintain mean arterial pressure (MAP) within a narrow range and have recently shown the controller was effective in both the operating room and intensive care unit. The controller has been used recently in a case series of three patients undergoing cardiac surgery and in five patients after cardiac surgery.

The investigators want to compare now a manual to a closed-loop titration of vasopressor infusion in patients admitted in the Intensive Care unit after cardiac surgery

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Computer guided vasopressor infusion
  • Behavioral: Manual control of vasopressor infusion
N/A

Detailed Description

Perioperative hypotension and arterial pressure variability have been shown to negatively impact patient outcomes, increasing risk of stroke, kidney injury, and myocardial injury among others.

Vasopressors are usually used to rapidly correct hypotension. Vasopressor infusions are typically administered by standard infusion pump with the rate adjusted by anesthesiologists to reach a predefined target mean arterial pressure (MAP); this requires frequent changes in the infusion rate because of the almost constantly changing hemodynamic status of such patients. Because it is infeasible for human providers to pay constant attention and make second-to-second changes, management is often suboptimal (i.e. large amounts of time are spent in hypotension below the target, or well above the target with the vasopressor drip still running).

The investigators have developed an automated closed-loop vasopressor (CLV) controller to improve the titration of vasopressor (e.g:noradrenaline) in order to maintain MAP within a narrow range in the perioperative setting. The investigators have published engineering, animal and most recently, pilot,studies or case series with promising results.

In this randomized controlled trial, the investigators will compare time spent in hypotension defined as a mean arterial pressure < 65 mmHg. They tested the hypothesis that the automated system will allow patients to spent less time during the postoperative period with a MAP < 65 mmHg. This is thus a superiority study over a two hours study period

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled superiority trialRandomized controlled superiority trial
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Postoperative Hypotension Management With Computer-guided Vasopressor Titration in High-Risk Patients After Cardiac Surgery: A Randomized Controlled Trial
Actual Study Start Date :
Nov 26, 2020
Actual Primary Completion Date :
Dec 17, 2020
Actual Study Completion Date :
Dec 17, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Manual control of vasopressor infusion

Vasopressor will be manually titrated by intensive care unit nurses in charge of the patients to maintain mean arterial pressure > 65 mmHg. Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period

Behavioral: Manual control of vasopressor infusion
manual adjustments of noradrenaline infusion

Experimental: Computer guided vasopressor infusion

Vasopressor will be titrated automatically by the closed-loop system to maintain mean arterial pressure > 65 mmHg. Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period

Behavioral: Computer guided vasopressor infusion
automated titration of vasopressor infusion to maintain a mean arterial pressure > 65mmHg

Outcome Measures

Primary Outcome Measures

  1. incidence of postoperative hypotension [postoperative hour 2]

    Percentage of treatment period spent with a MAP < 65 mmHg

Secondary Outcome Measures

  1. Number of vasopressor infusion rate modifications [postoperative hour 2]

    Number of vasopressor infusion rate modifications

  2. Amount of vasopressor [postoperative hour 2]

    Amount of noradrenaline received during surgery

  3. amount of fluid [postoperative hour 2]

    amount of fluid received during surgery

  4. incidence of acute kidney injury [postoperative day 7]

    incidence of acute kidney injury at postoperative day 7

  5. troponin values [postoperative day 0]

    troponin values at intensive care arrival

  6. troponin values [postoperative day 1]

    troponin values at postoperative day 1

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patient

  • Elective cardiac surgery

  • French speaking patient

Exclusion Criteria:
  • Uncontrolled hypertension

  • Renal insufficiency (estimated glomerular filtration rate < 30mL/min/1,73m²)

  • Left ejection fraction < 40%

  • Emergency surgery

  • Preoperative infection

  • Preoperative cardiac arrythmia

  • Pregnant women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinique de la Sauvegarde Lyon France 69009

Sponsors and Collaborators

  • Clinique de la Sauvegarde
  • Bicetre Hospital
  • Erasme University Hospital

Investigators

  • Principal Investigator: Olivier Desebbe, MD, Clinique de la Sauvegarde

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Clinique de la Sauvegarde
ClinicalTrials.gov Identifier:
NCT04586218
Other Study ID Numbers:
  • 2019-A03191-56
First Posted:
Oct 14, 2020
Last Update Posted:
Dec 22, 2020
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 22, 2020